POM-V Prescription Required Companion Animal

Metaxx 0.25 mg Chewable Tablets for Cats

Active ingredient: Meloxicam

Form

Chewable

Species

Cats

Manufacturer

Alfasan Nederland B.V.

VMD MA No.

36408/3016

What it's used for

Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Meloxicam

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Metaxx 0.25 mg Chewable Tablets for Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders.

Post-operative pain and inflammation following surgical procedures:
After initial treatment with a suitable injectable formulation of meloxicam authorised
for cats, continue treatment 24 hours later at a dosage of 0.05 mg meloxicam/kg
body weight. The oral follow-up dose may be administered once daily (at 24-hour
intervals) for up to four days.
Acute musculo-skeletal disorders:
Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight on the first
day. Treatment is to be continued once daily by oral administration (at 24-hour
intervals) at a dose of 0.05 mg meloxicam/kg body weight for as long as acute pain
and inflammation persist.
Chronic musculo-skeletal disorders:
Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight on the first
day. Treatment is to be continued once daily by oral administration (at 24-hour
intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight. A clinical
response is normally seen within 7 days. Treatment should be discontinued after 14
days at the latest if no clinical improvement is apparent.
Dosing table for maintenance dose of 0.05 mg/kg:
Weight
(kg)
tablet
1.25 – 2.2¼ tablet2.3 – 3.4½ tablet3.5– 4.5¾ tablet4.6 – 5.7 1 tablet5.8 - 71 ¼ tablet
The recommended dose should not be exceeded.
The tablets can be administered with or without food.
Chewable tablets can be divided into two or four equal parts, for dosage accuracy,
according to the bodyweight.

Do not use in pregnant or lactating cats.
Do not use in cats suffering from gastrointestinal disorders such as irritation and
haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic
disorders.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use in cats less than 6 weeks of age or weighing less than 1.25 kg.

Cats:
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Appetite loss, vomiting, diarrhoea, blood in
faeces*.
Lethargy*.
Renal failure *.
Gastrointestinal ulceration.
Elevated liver enzymes.
* Typical adverse reactions of NSAIDs
These side effects are in most cases transient and disappear following termination of
the treatment but in very rare cases may be serious or fatal. If adverse reactions
occur, treatment should be discontinued and the advice of a veterinarian should be
sought.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See section “Contact details” of the package leaflet.

None.

Special precautions for safe use in the target species:
Avoid use in any dehydrated, hypovolaemic or hypotensive cat, as there is a potential
risk of renal toxicity.
As the chewable tablets are flavoured, store tablets out of reach of cats to avoid
accidental ingestion.
Post-operative use:
In case additional pain relief is required, multimodal pain therapy should be
considered.
Chronic musculoskeletal disorders:
Response to long-term therapy should be monitored at regular intervals by a
veterinary surgeon.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Meloxicam and other non-steroidal anti-inflammatory drugs (NSAIDs) may cause
hypersensitivity reactions. People with known hypersensitivity to NSAIDs should
avoid contact with the veterinary medicinal product. Wash hands after use.
Accidental ingestion by children may be harmful. Unused tablet parts should
therefore be returned into the blister and carton and stored in a safe place. Part used
tablets should be used at the time of the next dose. In case of accidental ingestion by
a child seek medical advice immediately and show the package leaflet or the label to
the physician.
Special precautions for the protection of the environment:
Not applicable.

Other NSAIDs, diuretics, anticoagulant, aminoglycoside antibiotics and substances
with high protein binding may compete for binding and thus lead to toxic effects.
Meloxicam must not be administered in conjunction with other NSAIDs or
glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should
be avoided.
Pre-treatment with anti-inflammatory substances other than meloxicam at a single
dose of 0.2 mg/kg may result in additional or increased adverse effects and
accordingly a treatment-free period with such veterinary medicinal products should
be observed for at least 24 hours before commencement of treatment. The
treatment-free period, however, should take into account the pharmacological
properties of the products used previously.

This veterinary medicinal product does not require any special storage conditions.

Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.